P
Philippe Szapary
Researcher at Janssen Pharmaceutica
Publications - 101
Citations - 8533
Philippe Szapary is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Ustekinumab & Psoriasis. The author has an hindex of 43, co-authored 96 publications receiving 7692 citations. Previous affiliations of Philippe Szapary include Johnson & Johnson & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
A randomized trial of a low-carbohydrate diet for obesity.
Gary D. Foster,Holly R. Wyatt,James O. Hill,Brian G. McGuckin,Carrie Brill,B. Selma Mohammed,Philippe Szapary,Daniel J. Rader,Joel S. Edman,Samuel Klein +9 more
TL;DR: The low-carbohydrate diet produced a greater weight loss than did the conventional diet for the first six months, but the differences were not significant at one year and the low- carbohydrate diet was associated with a greater improvement in some risk factors for coronary heart disease.
Journal ArticleDOI
Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia
Marina Cuchel,LeAnne T. Bloedon,Philippe Szapary,Daniel M. Kolansky,Megan L. Wolfe,Antoine Sarkis,John S. Millar,Katsunori Ikewaki,Evan S. Siegelman,Richard E. Gregg,Daniel J. Rader +10 more
TL;DR: Inhibition of the microsomal triglyceride transfer protein by BMS-201038 resulted in the reduction of LDL cholesterol levels in patients with homozygous familial hypercholesterolemia, owing to reduced production of apolipoprotein B.
Journal Article
Therapeutic applications of fenugreek.
TL;DR: Preliminary animal and human trials suggest possible hypoglycemic and antihyperlipidemic properties of oral fenugreek seed powder.
Journal ArticleDOI
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Kim A. Papp,Christopher E.M. Griffiths,Kenneth B. Gordon,Mark Lebwohl,Philippe Szapary,Y. Wasfi,Daphne Chan,M-C Hsu,Ho,Pierre-Dominique Ghislain,Bruce Strober,Kristian Reich +11 more
TL;DR: Long‐term safety evaluations of biologics are needed to inform patient management decisions and should be considered in clinical practice, according to a report in JAMA Oncology.
Journal ArticleDOI
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen,Stacy Smith,Robert Matheson,Craig L. Leonardi,Cesar Calderon,Carrie Brodmerkel,Katherine Li,Kim Campbell,Stanley J. Marciniak,Y. Wasfi,Y. Wang,Philippe Szapary,James G. Krueger +12 more
TL;DR: IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe Psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis.